Clinical Trial Update: The Effect of Erythropoietin in the Treatment of Scleral Necrosis [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial investigating erythropoietin for treating scleral necrosis (conjunctival and scleral avascular lesions).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conjunctival and Scleral Avascular Lesions

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Shahid Beheshti University of Medical Sciences | Conditions: Conjunctival and Scleral Avascular Lesions | Phase 2, Phase 3 | Status: UNKNOWN